153 related articles for article (PubMed ID: 12499213)
1. Activities of moxifloxacin alone and in combination with other antimicrobial agents against multidrug-resistant Mycobacterium tuberculosis infection in BALB/c mice.
Fattorini L; Tan D; Iona E; Mattei M; Giannoni F; Brunori L; Recchia S; Orefici G
Antimicrob Agents Chemother; 2003 Jan; 47(1):360-2. PubMed ID: 12499213
[TBL] [Abstract][Full Text] [Related]
2. Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model.
Poissy J; Aubry A; Fernandez C; Lott MC; Chauffour A; Jarlier V; Farinotti R; Veziris N
Antimicrob Agents Chemother; 2010 Nov; 54(11):4765-71. PubMed ID: 20805388
[TBL] [Abstract][Full Text] [Related]
3. Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model.
Nuermberger E; Tyagi S; Williams KN; Rosenthal I; Bishai WR; Grosset JH
Am J Respir Crit Care Med; 2005 Dec; 172(11):1452-6. PubMed ID: 16151038
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis.
Alvirez-Freites EJ; Carter JL; Cynamon MH
Antimicrob Agents Chemother; 2002 Apr; 46(4):1022-5. PubMed ID: 11897584
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis.
Rodríguez JC; Ruiz M; López M; Royo G
Int J Antimicrob Agents; 2002 Dec; 20(6):464-7. PubMed ID: 12458143
[TBL] [Abstract][Full Text] [Related]
6. Interactions of linezolid and second-line anti-tuberculosis agents against multidrug-resistant Mycobacterium tuberculosis in vitro and in vivo.
Zhao W; Zheng M; Wang B; Mu X; Li P; Fu L; Liu S; Guo Z
Int J Infect Dis; 2016 Nov; 52():23-28. PubMed ID: 27613365
[TBL] [Abstract][Full Text] [Related]
7. In vitro postantibiotic effects of rifapentine, isoniazid, and moxifloxacin against Mycobacterium tuberculosis.
Chan CY; Au-Yeang C; Yew WW; Leung CC; Cheng AF
Antimicrob Agents Chemother; 2004 Jan; 48(1):340-3. PubMed ID: 14693563
[TBL] [Abstract][Full Text] [Related]
8. A Faropenem, Linezolid, and Moxifloxacin Regimen for Both Drug-Susceptible and Multidrug-Resistant Tuberculosis in Children: FLAME Path on the Milky Way.
Deshpande D; Srivastava S; Nuermberger E; Pasipanodya JG; Swaminathan S; Gumbo T
Clin Infect Dis; 2016 Nov; 63(suppl 3):S95-S101. PubMed ID: 27742640
[TBL] [Abstract][Full Text] [Related]
9. Bactericidal activity of moxifloxacin on exponential and stationary phase cultures of Mycobacterium tuberculosis.
Sulochana S; Mitchison DA; Kubendiren G; Venkatesan P; Paramasivan CN
J Chemother; 2009 Apr; 21(2):127-34. PubMed ID: 19423464
[TBL] [Abstract][Full Text] [Related]
10. [Present and future in the use of anti-tubercular drugs].
Didilescu C; Craiova UM
Pneumologia; 2011; 60(4):198-201. PubMed ID: 22420168
[TBL] [Abstract][Full Text] [Related]
11. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis.
Nuermberger E; Tyagi S; Tasneen R; Williams KN; Almeida D; Rosenthal I; Grosset JH
Antimicrob Agents Chemother; 2008 Apr; 52(4):1522-4. PubMed ID: 18285479
[TBL] [Abstract][Full Text] [Related]
12. Isoniazid-resistant intracranial tuberculoma treated with a combination of moxifloxacin and first-line anti-tuberculosis medication.
Lee WY; Ling M; Anderson G; Achawal S; Thaker HK
J Med Microbiol; 2011 Oct; 60(Pt 10):1550-1552. PubMed ID: 21659503
[TBL] [Abstract][Full Text] [Related]
13. [Determination of in vitro synergy by a checkerboard method when 3 core antimicrobial agents of the retreatment new scheme combined against MDR-MTB and XDR-MTB].
Zhang LL; Yang H; Xiao HP; Lu JM; Sha W; Zhang Q
Zhonghua Jie He He Hu Xi Za Zhi; 2016 Jun; 39(6):464-8. PubMed ID: 27289577
[TBL] [Abstract][Full Text] [Related]
14. Synergistic activities of clofazimine with moxifloxacin or capreomycin against Mycobacterium tuberculosis in China.
Li G; Xu Z; Jiang Y; Liu H; Zhao LL; Li M; Xu D; Zhao X; Liu Z; Wang R; Wan K
Int J Antimicrob Agents; 2019 Nov; 54(5):642-646. PubMed ID: 31200023
[TBL] [Abstract][Full Text] [Related]
15. Should moxifloxacin be substituted for isoniazid as a first-line antituberculosis drug?
Mohapatra PR
Am J Respir Crit Care Med; 2009 Oct; 180(7):686; author reply 686-7. PubMed ID: 19762595
[No Abstract] [Full Text] [Related]
16. Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice.
Lounis N; Bentoucha A; Truffot-Pernot C; Ji B; O'Brien RJ; Vernon A; Roscigno G; Grosset J
Antimicrob Agents Chemother; 2001 Dec; 45(12):3482-6. PubMed ID: 11709328
[TBL] [Abstract][Full Text] [Related]
17. Effect of coadministration of moxifloxacin and rifampin on Mycobacterium tuberculosis in a murine aerosol infection model.
Balasubramanian V; Solapure S; Gaonkar S; Mahesh Kumar KN; Shandil RK; Deshpande A; Kumar N; Vishwas KG; Panduga V; Reddy J; Ganguly S; Louie A; Drusano GL
Antimicrob Agents Chemother; 2012 Jun; 56(6):3054-7. PubMed ID: 22470118
[TBL] [Abstract][Full Text] [Related]
18. Activity of moxifloxacin against mycobacteria.
Gillespie SH; Billington O
J Antimicrob Chemother; 1999 Sep; 44(3):393-5. PubMed ID: 10511409
[TBL] [Abstract][Full Text] [Related]
19. Thiosemicarbazole (thiacetazone-like) compound with activity against Mycobacterium avium in mice.
Bermudez LE; Reynolds R; Kolonoski P; Aralar P; Inderlied CB; Young LS
Antimicrob Agents Chemother; 2003 Aug; 47(8):2685-7. PubMed ID: 12878542
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and in vitro evaluation of novel substituted isatin-propylene-1H-1,2,3-triazole-4-methylene-moxifloxacin hybrids for their anti-mycobacterial activities.
Yan X; Lv Z; Wen J; Zhao S; Xu Z
Eur J Med Chem; 2018 Jan; 143():899-904. PubMed ID: 29227930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
